Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

The North Carolina firm convinced investors to pledge $88 million and layered $50 million in federal small-business loans on top. It has quickly put the funds to work.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.